Axovant Sciences Ltd. (AXON) to Release Earnings on Monday
Axovant Sciences Ltd. (NYSE:AXON) will release its earnings data before the market opens on Monday, August 14th. Analysts expect Axovant Sciences to post earnings of ($0.53) per share for the quarter.
Axovant Sciences (NYSE:AXON) last announced its quarterly earnings results on Tuesday, June 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. On average, analysts expect Axovant Sciences to post $-2.14 EPS for the current fiscal year and $-2.62 EPS for the next fiscal year.
Axovant Sciences Ltd. (AXON) opened at 23.40 on Monday. Axovant Sciences Ltd. has a 52 week low of $11.01 and a 52 week high of $26.49. The firm has a 50-day moving average of $22.85 and a 200 day moving average of $18.65. The stock’s market capitalization is $2.51 billion.
AXON has been the topic of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research report on Friday, June 9th. CIBC upped their target price on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Oppenheimer Holdings, Inc. upped their target price on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. BidaskClub raised Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Zacks Investment Research lowered Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Axovant Sciences currently has an average rating of “Buy” and a consensus target price of $28.50.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.